Buzz Stocks: Home Depot Inc, Fitbit Inc, and Valeant Pharmaceuticals Intl Inc

Today's stocks to watch include Home Depot Inc (HD), Fitbit Inc (FIT), and Valeant Pharmaceuticals Intl Inc (VRX)

Feb 23, 2016 at 10:04 AM

U.S. stocks are down this morning amid a slip in oil futures. Meanwhile, do-it-yourself retailer Home Depot Inc (NYSE:HD), wearables expert Fitbit Inc (NYSE:FIT), and drugmaker Valeant Pharmaceuticals Intl Inc (NYSE:VRX) are among the equities in focus today.

HD reported better-than-forecast quarterly earnings and sales this morning, boosted its quarterly dividend by 17%, and announced a $5 billion stock repurchase plan. Collectively, the news has the shares 2.5% higher at $125.91 -- though they're still down 4.8% year-to-date. On Wall Street, analysts are firmly in HD's bullish camp, with 11 of 17 brokerages handing out "buy" or better ratings, compared to six "holds" and not a single "sell" opinion. Earlier, in fact, Morgan Stanley boosted its price target to $145 from $135, calling the stock a "beacon of strength in an increasingly bumpy macro and retail backdrop." Elsewhere, short interest on Home Depot Inc fell nearly 30% during the last two reporting periods, and now makes up less than 1% of its total float.

FIT has tumbled over 16% this morning to trade at $14.82, as lackluster current-quarter guidance overshadows a huge earnings beat. Making matters worse, the stock is facing a flood of negative analyst attention. No fewer than 10 brokerages weighed in on Fitbit Inc, and among them were Stifel and Baird, which both lowered their ratings to the equivalent of "hold." There's plenty of room for additional bearish notes, too, as 16 of 21 analysts maintain "buy" or better assessments on the stock -- with not a single "sell" opinion to be found. Since its record high of $51.90 in early August, FIT has tumbled nearly 73%.

VRX is up 9.4% at $83.07, after the pharmaceutical firm said it will need to restate its earnings for 2014 and 2015 based on the results of an internal probe. Longer term, though, it's been a brutal few months for the stock, which has shed roughly two-thirds of its value since its most recent high of $245.82 in late September, largely due to Citron Research's short-seller report and the recent release of some damning congressional documents. Of course, none of this has stopped option traders from betting bullishly on Valeant Pharmaceuticals Intl Inc. The stock's 50-day call/put volume ratio across the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) checks in at 1.70, in the 88th percentile of its annual range.

Sign up now for Schaeffer's Opening View newsletter to get a head start on all the major pre-market news!

Follow @Schaeffers

$40 Gets You 4 High-Conviction Trades. Let's Go.

We just booked back-to-back double-digit gains on Celsius and Palantir in Trade of the Week, and we’re eyeing even bigger wins!

Every week starts with a fully defined options trade straight from the desk Schaeffer’s Senior V.P. of Research, Todd Salamone, backed by 30+ years of proven market experience and disciplined risk management.

Right now, you can get 4 total trades over the next 4 weeks for $40 – just $10 per trade.

👉 Sign Up Now to Receive Your First Trade!